Official Guidance: Semaglutide Now Recommended for Fatty Liver Disease With Significant Scarring
The AASLD now recommends semaglutide 2.4 mg/week for MASH with moderate-to-advanced fibrosis, based on FDA approval showing 63% achieved disease resolution versus 34% on placebo.
Quick Facts
What This Study Found
The AASLD updated its practice guidance to incorporate semaglutide for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. Semaglutide (Wegovy formulation, 2.4 mg/week subcutaneous) received accelerated FDA approval in August 2025 based on the ESSENCE trial, which showed:
- MASH resolution without worsening fibrosis: 62.9% vs 34.3% placebo
- Fibrosis improvement by ≥1 stage without worsening MASH: 37.0% vs 22.5% placebo
The guidance recommends semaglutide for MASH with F2-F3 fibrosis, with careful monitoring for patients with compensated cirrhosis. Lifestyle modification remains the cornerstone alongside drug therapy.
Key Numbers
62.9% vs 34.3% MASH resolution · 37.0% vs 22.5% fibrosis improvement · 2.4 mg/week dose · 72 weeks · F2-F3 fibrosis indication · ALT reduction ≥17 U/L or ≥20% suggests response
How They Did This
AASLD clinical practice guidance update based on the ESSENCE phase 3 trial interim results. Provides recommendations for patient selection, treatment monitoring using non-invasive tests (VCTE, MRE, ELF, FIB-4), safety monitoring, and assessment of treatment response.
Why This Research Matters
This is a landmark moment in liver disease treatment — semaglutide becomes the second FDA-approved drug for MASH (after resmetirom), addressing a condition that affects tens of millions of people and was previously untreatable. The AASLD guidance provides clinicians with the first official roadmap for patient selection, monitoring, and safety management.
The Bigger Picture
MASH is the fastest-growing cause of liver transplantation worldwide, and until 2024 there were no approved drugs. With resmetirom (approved 2024) and now semaglutide (2025), the treatment landscape has transformed. Semaglutide's additional metabolic benefits (weight loss, cardiovascular protection) make it particularly compelling for MASH patients, who typically have multiple metabolic comorbidities.
What This Study Doesn't Tell Us
Based on accelerated FDA approval with interim trial results — long-term outcomes data are still pending. Combination use with resmetirom has not been studied. Non-invasive tests cannot reliably predict individual histologic response. The guidance does not cover patients with decompensated cirrhosis or those with advanced fibrosis markers suggesting cirrhosis.
Questions This Raises
- ?Will combining semaglutide with resmetirom provide additive liver benefits?
- ?How long should semaglutide treatment continue for MASH — indefinitely or until specific endpoints are met?
- ?Will semaglutide's MASH indication expand to patients with compensated cirrhosis as more data emerge?
Trust & Context
- Key Stat:
- 62.9% resolution MASH resolution rate with semaglutide 2.4 mg/week at 72 weeks versus 34.3% placebo in the ESSENCE trial
- Evidence Grade:
- This is an official AASLD practice guidance based on a phase 3 randomized controlled trial (ESSENCE) with FDA approval. While the approval is accelerated (pending confirmatory data), the evidence supporting the recommendation is robust from a large clinical trial.
- Study Age:
- Published in 2025, this guidance reflects the most current evidence and FDA approval status for semaglutide in MASH treatment. The field is rapidly evolving.
- Original Title:
- Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
- Published In:
- Hepatology (Baltimore, Md.) (2025)
- Authors:
- Bansal, Meena B(2), Patton, Heather, Morgan, Timothy R, Carr, Rotonya M, Dranoff, Jonathan A, Allen, Alina M
- Database ID:
- RPEP-10075
Evidence Hierarchy
Frequently Asked Questions
Is semaglutide FDA-approved for fatty liver disease?
Yes — as of August 2025, the Wegovy formulation of semaglutide received accelerated FDA approval for treating MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis. In the ESSENCE trial, nearly 63% of patients saw their liver disease resolve after 72 weeks of treatment.
Who should consider semaglutide for liver disease?
According to the AASLD guidance, semaglutide is recommended for adults with MASH and moderate-to-advanced liver scarring (F2-F3 fibrosis). Patients with compensated cirrhosis who are already on semaglutide for another reason should be monitored carefully. The drug should be combined with lifestyle modifications including diet and exercise.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10075APA
Bansal, Meena B; Patton, Heather; Morgan, Timothy R; Carr, Rotonya M; Dranoff, Jonathan A; Allen, Alina M. (2025). Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.. Hepatology (Baltimore, Md.). https://doi.org/10.1097/HEP.0000000000001608
MLA
Bansal, Meena B, et al. "Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.." Hepatology (Baltimore, 2025. https://doi.org/10.1097/HEP.0000000000001608
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide therapy for metabolic dysfunction-associated ste..." RPEP-10075. Retrieved from https://rethinkpeptides.com/research/bansal-2025-semaglutide-therapy-for-metabolic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.